On November 4, 2025, Pacira BioSciences, a leader in non-opioid pain management, announced an exclusive worldwide license and collaboration agreement with AmacaThera to develop and commercialize AMT-143, an investigational long‑acting formulation of the non‑opioid analgesic ropivacaine for postsurgical pain control. Wilson Sonsini Goodrich & Rosati advised Pacira BioSciences on the transaction.

Under the terms of the agreement, Pacira BioSciences will fund clinical development through to commercial launch. Additionally, the companies will collaborate on Phase 2 clinical development. AmacaThera will receive an upfront payment of $5 million with the potential for future milestone payments.

The Wilson Sonsini team that advised Pacira on the transaction includes Seth Flaum and Aleks Vitomirov.

For more information, please see Pacira BioSciences' news release.